ATAI Life Sciences
ATAI

$1.59

3.16%

Market Cap: 266M

About: ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.

Employees: 83

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 4 analysts

0

News positive %

of 6 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

30% more capital invested

Capital invested by funds: $18.7M [Q4 2023] → $24.3M (+$5.61M) [Q1 2024]

24% more call options, than puts

Call options by funds: $1.18M | Put options by funds: $953K

0% more funds holding

Funds holding: 84 [Q4 2023] → 84 (+0) [Q1 2024]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 1 (+0) [Q1 2024]

0% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 14

0.56% less ownership

Funds ownership: 7.99% [Q4 2023] → 7.43% (-0.56%) [Q1 2024]

29% less repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 21

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$6

277%

upside

Avg. target

$14

781%

upside

High target

$20

1,158%

upside

4 analyst ratings

4 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Patrick Trucchio	843%upside $15	Buy Reiterated	17 May 2024
Maxim Group Jason McCarthy	277%upside $6	Buy Upgraded	3 Apr 2024
HC Wainwright & Co. Patrick Trucchio	843%upside $15	Buy Maintained	3 Apr 2024
HC Wainwright & Co. Patrick Trucchio	1,158%upside $20	Buy Maintained	27 Mar 2024

See Analyst Rankings

Financial journalist opinion

Based on 6 articles about ATAI published over the past 30 days

Zacks Investment Research

atai Life Sciences (ATAI) Upgraded to Buy: Here's What You Should Know

atai Life Sciences (ATAI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

atai Life Sciences (ATAI) Upgraded to Buy: Here's What You Should Know

3 Dirt-Cheap Drug Developers With Blockbuster Potential

One of the more exciting yet admittedly risky types of investing is buying into cheap drug developer stocks early in their company life cycle. That's because the world of drug development and biotech research tends to rely on big market-moving moments like regulatory approvals and clinical trial results.

3 Dirt-Cheap Drug Developers With Blockbuster Potential

3 Next-Gen Drug Stocks Exploring Psychedelic Frontiers

Although psychedelic drug stocks have lost some of their earlier momentum, significant research and advancements continue under the radar. Even high-profile figures like Elon Musk reportedly use ketamine for depression, highlighting the ongoing interest in non-standard treatment protocols often associated with psychedelic stocks (though ketamine itself isn't a psychedelic, it does fall within the “alternative therapeutics” camp that psychedelic drug stocks often occupy).

3 Next-Gen Drug Stocks Exploring Psychedelic Frontiers

3 Psychedelic Stocks to Ride to the Moon and Beyond

The value of the psychedelic market is expected to approximately triple over the next few years. While not a large market in absolute terms, that growth potential will create many winning stocks.

3 Psychedelic Stocks to Ride to the Moon and Beyond

3 Psychedelic Stocks to Buy on the Dip: Summer 2024

While the cannabis industry has all but become legitimate in the United States, it's not the only form of alternative medicine attempting to break through regulatory barriers. Compounds like psilocybin, lysergic acid and ketamine are all referred to as psychedelics, yet they may have medical applications which are just beginning to be explored.

3 Psychedelic Stocks to Buy on the Dip: Summer 2024

Proactive Investors

atai Life Sciences CEO talks successful Phase 1 trial of IV psilocin formulation – ICYMI

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) recently welcomed encouraging results from Beckley Pystech's Phase 1 trial of its patient-protected intravenous (IV) formulation of psilocin ELE-101 in patients with major depressive disorder. The company owned a 35.5% stake in Beckley Psytech.

atai Life Sciences CEO talks successful Phase 1 trial of IV psilocin formulation – ICYMI

atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference

NEW YORK and BERLIN, June 26, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company's management team will participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference taking place on June 27, 2024. Details of the company's participation:

atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference

Proactive Investors

atai Life Sciences optimistic as IV psilocin shows promise in treating depression in early trial

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has welcomed promising initial results from Beckley Psytech's Phase1 trial of its patient-protected intravenous (IV) formulation of psilocin ELE-101 in patients with major depressive disorder. Beckley Psytech, a private clinical-stage biopharmaceutical company in which atai holds a 35.5% ownership stake, reported that initial data from Phase 1 single ascending dose study in healthy participants showed that ELE-101 was well-tolerated, with no serious or severe adverse events reported, and demonstrated a dose-proportional profile, which leads to reduced variability between patients when compared to oral psilocybin.

atai Life Sciences optimistic as IV psilocin shows promise in treating depression in early trial

atai Life Sciences Announces Update on Beckley Psytech's Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a

NEW YORK and BERLIN, June 20, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced an update on Beckley Psytech's Phase 1/2a trial of ELE-101 (NCT05434156) for people living with MDD, with initial results from Phase 1 and the dosing of the first patients in the Phase 2a part of the study.

atai Life Sciences Announces Update on Beckley Psytech's Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a

Proactive Investors

atai Life Sciences poised for success with rigorous clinical trials

Analysts at Jefferies remain bullish on atai Life Sciences (NASDAQ:ATAI, ETR:9VC) as the broader psychedelic space this week hit a “technical setback.” On June 4, Lykos Therapeutics brought its application for MDMA-assisted therapy for post-traumatic stress disorder before the Food and Drug Administration (FDA) Advisory Committee (AdCom).

atai Life Sciences poised for success with rigorous clinical trials

See News Rankings